双重向PPARα和NPC1L1代谢漏洞阻断了瘤的发生
Xiaona You1, Xi Hu2, Zenghui Sun2
1Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China; School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
针对乳腺癌中的脂质代谢,这项研究发现,抑制尼曼-皮克C1-like 1 (NPC1L1) 以及激活过氧酶增殖器激活受体α (PPARα) 诱导癌细胞死亡并抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢途径 代谢途径
背景情况:
- 不调节的脂质代谢是癌症的标志,影响瘤的进展.
- PKM2 (Pyruvate Kinase M2) 在癌症代谢中起作用,但其下游作用者尚未完全理解.
- 尼曼-皮克C1-like 1 (NPC1L1) 参与胆固醇吸收,其在癌症中的作用正在出现.
研究的目的:
- 研究NPC1L1作为乳腺癌中PKM2下游点的作用.
- 探索针对乳腺癌中NPC1L1和PPARα信号的治疗潜力.
主要方法:
- 使用PKM2淘汰 (KO) 乳腺癌细胞模型.
- 研究了费诺纤维酸 (PPARα激活剂) 和埃泽蒂米布 (NPC1L1抑制剂) 对细胞亡和瘤生长的影响.
- 分析了分子机制,包括转录因子的招募,IRE1α/XBP1s通路的激活,以及组织蛋白修饰 (H3K27脱甲基化).
主要成果:
- PKM2 KO增强了NPC1L1表达,并降低了PPARα信号的调节.
- 费诺纤维酸和ezetimibe通过IRE1α/XBP1s/KDM6B通路激活和H3K27乙化协同诱导乳腺癌细胞亡.
- 联合治疗在体内显著抑制了瘤生长.
结论:
- 在乳腺癌中,NPC1L1是PKM2的下游效应因子.
- 双重向PPARα和NPC1L1为乳腺癌提供了一个有前途的新疗法策略.
- IRE1α/XBP1s/KDM6B轴调解了联合费诺纤维酸和埃泽胺治疗的抗癌作用.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
相关概念视频
Abnormal Proliferation
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
